Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Google Secures Pentagon AI Deal for Classified Projects 
 - EconoTimes)
SOUTH SAN FRANCISCO, Calif., May 09, 2017 -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that clinical results from the Phase 2 study of cerdulatinib in patients with relapsed/refractory b-cell malignancies will be shared in an oral presentation at the International Conference on Malignant Lymphoma (ICML), which is taking place from June 14-17 in Lugano, Switzerland.
Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancers. Cerdulatinib inhibits two key signaling pathways that promote cancer cell growth in certain hematologic malignancies.
Details regarding the oral presentation follow.
Oral Presentation Details:
- Abstract Title: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B-Cell Malignancies
- Presenting Author: P.A. Hamlin, Memorial Sloan Kettering Cancer Center
- Presentation Date and Time: June 15, 2017 at 4:40 p.m. CEST
- Location: Room A, Cinema Corso and Aula Magna (Lugano University)
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart Pure Communications [email protected] 415.946.1087
